Ni X - Search Results

1

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Duvic M, et al. Among authors: ni x. Blood. 2007 Jan 1;109(1):31-9. doi: 10.1182/blood-2006-06-025999. Epub 2006 Sep 7. Blood. 2007. PMID: 16960145 Free PMC article. Clinical Trial.

2

Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?

Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Ni X, et al. Clin Cancer Res. 2001 Sep;7(9):2682-92. Clin Cancer Res. 2001. PMID: 11555580

3

Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.

Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Zhang C, et al. Among authors: ni x. Clin Cancer Res. 2002 May;8(5):1234-40. Clin Cancer Res. 2002. PMID: 12006543

4

Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.

Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Joseph A, Hazarika P. Duvic M, et al. Among authors: ni x. J Invest Dermatol. 2003 Oct;121(4):902-9. doi: 10.1046/j.1523-1747.2003.12488.x. J Invest Dermatol. 2003. PMID: 14632211 Free article. Clinical Trial.

5

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.

Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Apisarnthanarax N, et al. Among authors: ni x. J Am Acad Dermatol. 2004 Apr;50(4):600-7. doi: 10.1016/j.jaad.2003.09.005. J Am Acad Dermatol. 2004. PMID: 15034511 Clinical Trial.

6

The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.

Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. Zhang C, et al. Among authors: ni x. J Invest Dermatol. 2004 Aug;123(2):380-7. doi: 10.1111/j.0022-202X.2004.23207.x. J Invest Dermatol. 2004. PMID: 15245439 Free article.

7

Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.

Ni X, Zhang C, Talpur R, Duvic M. Ni X, et al. J Invest Dermatol. 2005 Apr;124(4):741-50. doi: 10.1111/j.0022-202X.2005.23657.x. J Invest Dermatol. 2005. PMID: 15816832 Free article.

8

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.

Zhang C, Richon V, Ni X, Talpur R, Duvic M. Zhang C, et al. Among authors: ni x. J Invest Dermatol. 2005 Nov;125(5):1045-52. doi: 10.1111/j.0022-202X.2005.23925.x. J Invest Dermatol. 2005. PMID: 16297208 Free article.

9

Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.

Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, Duvic M. Doherty SD, et al. Among authors: ni x. Arch Dermatol Res. 2006 Dec;298(7):353-6. doi: 10.1007/s00403-006-0705-x. Epub 2006 Sep 26. Arch Dermatol Res. 2006. PMID: 17021762

10

Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.

Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, Duvic M. Ni X, et al. J Invest Dermatol. 2008 Nov;128(11):2631-2639. doi: 10.1038/jid.2008.125. Epub 2008 May 15. J Invest Dermatol. 2008. PMID: 18480841 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,541 results

Search Page

Filters